Modeling Fragile X Syndrome pp 337-357

Part of the Results and Problems in Cell Differentiation book series (RESULTS, volume 54)

The Fragile X-Associated Tremor Ataxia Syndrome



Fragile X-associated tremor/ataxia syndrome (FXTAS) is an adult-onset neurodegenerative disorder clinically characterized by intention tremor and gait ataxia, in addition to other conditions including hypothyroidism, autonomic dysfunction, hypertension, peripheral neuropathy, and cognitive decline. FXTAS affects some males (approximately 40%) and in less degree female premutation carriers (8–16%) older than 50 years with an age-dependent symptomatology and penetrance. The CGG repeat number appears to influence the severity and the age of onset of the disorder. The neuropathological hallmark of FXTAS is the presence of eosinophillic, ubiquitin-positive intranuclear inclusions in both neurons and astroglia throughout brain. FXTAS is due to RNA toxicity caused by elevated levels of CGG-expanded mRNA containing 55–200 CGG repeats, which is found in the intranuclear inclusions that sequester various proteins including ubiquitin, αB-crystallin, lamin A/C, hnRNP A2, myelin basic protein, and Sam68. The expression of the expanded CGG repeat FMR1 mRNA also induces a cellular stress response and leads to a disruption of the nuclear lamin A/C architecture. These alterations are observable even in early development, suggesting that the expanded-repeat mRNA triggers pathogenic mechanisms that can provide a molecular basis for the neurodevelopmental abnormalities observed in some children who are carriers of an FMR1 premutation allele. Finally, the presence of cellular dysregulation in older adults who do not present clinical features of FXTAS may suggest that additional genetic or environmental protective factors may play a role in the pathogenesis of FXTAS.


  1. Adams JS, Adams PE, Nguyen D, Brunberg JA, Tassone F, Zhang W, Koldewyn K, Rivera SM, Grigsby J, Zhang L, DeCarli C, Hagerman PJ, Hagerman RJ (2007) Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS). Neurology 69(9):851–859PubMedGoogle Scholar
  2. Adams PE, Adams JS, Nguyen DV, Hessl D, Brunberg JA, Tassone F, Zhang W, Koldewyn K, Rivera SM, Grigsby J, Zhang L, Decarli C, Hagerman PJ, Hagerman RJ (2010) Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers. Am J Med Genet B Neuropsychiatr Genet 153B(3):775–785PubMedGoogle Scholar
  3. Akins RS, Boyd A, Coffey S, Kaur I, Bailey B, Tassone F, Nguyen D, Hagerman RJ (2008) High frequency of migraine in FMR1 premutation carriers. 11th International Fragile X Conference. St. Louis, MOGoogle Scholar
  4. Allen EG, He W, Yadav-Shah M, Sherman SL (2004) A study of the distributional characteristics of FMR1 transcript levels in 238 individuals. Hum Genet 114(5):439–447PubMedGoogle Scholar
  5. Allingham-Hawkins DJ, Brown CA, Babul R, Chitayat D, Krekewich K, Humphries T, Ray PN, Teshima IE (1996) Tissue-specific methylation differences and cognitive function in fragile X premutation females. Am J Med Genet 64(2):329–333PubMedGoogle Scholar
  6. Arocena DG, Iwahashi CK, Won N, Beilina A, Ludwig AL, Tassone F, Schwartz PH, Hagerman PJ (2005) Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Hum Mol Genet 14(23):3661–3671PubMedGoogle Scholar
  7. Aziz M, Stathopulu E, Callias M, Taylor C, Turk J, Oostra B, Willemsen R, Patton M (2003) Clinical features of boys with fragile X premutations and intermediate alleles. Am J Med Genet 121B(1):119–127PubMedGoogle Scholar
  8. Bacalman S, Farzin F, Bourgeois JA, Cogswell J, Goodlin-Jones BL, Gane LW, Grigsby J, Leehey MA, Tassone F, Hagerman RJ (2006) Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. J Clin Psychiatry 67(1):87–94PubMedGoogle Scholar
  9. Bailey DBRM Jr, Olmsted M, Holiday DB (2008) Co-occurring conditions associated with FMR1 gene variations: findings from a National Parent Survey. Am J Med Genet 146A:2060–2069PubMedGoogle Scholar
  10. Bailey D, Skinner D, Tassone F, Berry-Kravis E, Sorenson P, Hagerman R (2010) Newborn screening for fragile X: Initial Reports from a Prospective Study. 12th International Fragile X Conference. Detroit, Michigan, pp 80–81Google Scholar
  11. Berry-Kravis E, Potanos K, Weinberg D, Zhou L, Goetz CG (2005) Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation. Ann Neurol 57(1):144–147PubMedGoogle Scholar
  12. Bontekoe CJ, Bakker CE, Nieuwenhuizen IM, van der Linde H, Lans H, de Lange D, Hirst MC, Oostra BA (2001) Instability of a (CGG)98 repeat in the Fmr1 promoter. Hum Mol Genet 10(16):1693–1699PubMedGoogle Scholar
  13. Bourgeois J, Coffey S, Rivera S, Hessl D, Gane L, Tassone F, Greco C, Finucane B, Nelson L, Berry-Kravis E, Grigsby J, Hagerman P, Hagerman R (2009) Fragile X premutation disorders – expanding the psychiatric perspective. J Clin Psychiatry 70(6):852–862PubMedGoogle Scholar
  14. Bourgeois JA, Seritan AL, Casillas EM, Hessl D, Schneider A, Yang Y, Kaur I, Cogswell JB, Nguyen DV, Hagerman RJ (2011) Lifetime prevalence of mood and anxiety disorders in fragile x premutation carriers. J Clin Psychiatry 72(2):175–182PubMedGoogle Scholar
  15. Brega AG, Goodrich G, Bennett RE, Hessl D, Engle K, Leehey MA, Bounds LS, Paulich MJ, Hagerman RJ, Hagerman PJ, Cogswell JB, Tassone F, Reynolds A, Kooken R, Kenny M, Grigsby J (2008) The primary cognitive deficit among males with fragile X-associated tremor/ataxia syndrome (FXTAS) is a dysexecutive syndrome. J Clin Exp Neuropsychol 30(8):853–69Google Scholar
  16. Brouwer JR, Severijnen E, de Jong FH, Hessl D, Hagerman RJ, Oostra BA, Willemsen R (2008) Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome. Psychoneuroendocrinology 33(6):863–873PubMedGoogle Scholar
  17. Brunberg JA, Jacquemont S, Hagerman RJ, Berry-Kravis E, Grigsby J, Leehey M, Tassone F, Brown WT, Greco C, Hagerman PJ (2002) Fragile X premutation carriers: characteristic MR imaging findings in adult males with progressive cerebellar and cognitive dysfunction. Am J Neuroradiol 23(10):1757–1766PubMedGoogle Scholar
  18. Charlet-Berguerand N, Sellier C (2010) DROSHA/DGCR8 sequestration by expanded CGG repeats leads to global micro-RNA processing alteration in FXTAS. 12th International Fragile X Conference. Detriot, Michigan, p 76Google Scholar
  19. Chen Y, Tassone F, Berman RF, Hagerman PJ, Hagerman RJ, Willemsen R, Pessah IN (2010) Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet 19(1):196–208PubMedGoogle Scholar
  20. Coffey SM, Cook K, Tartaglia N, Tassone F, Nguyen DV, Pan R, Bronsky HE, Yuhas J, Borodyanskaya M, Grigsby J, Doerflinger M, Hagerman PJ, Hagerman RJ (2008) Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A 146A(8):1009–1016PubMedGoogle Scholar
  21. Cohen S, Masyn K, Adams J, Hessl D, Rivera S, Tassone F, Brunberg J, DeCarli C, Zhang L, Cogswell J, Loesch D, Leehey M, Grigsby J, Hagerman PJ, Hagerman RJ (2006) Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome. Neurology 67(8):1426–1431PubMedGoogle Scholar
  22. Cronister A, Schreiner R, Wittenberger M, Amiri K, Harris K, Hagerman RJ (1991) Heterozygous fragile X female: historical, physical, cognitive, and cytogenetic features. Am J Med Genet 38(2–3):269–274PubMedGoogle Scholar
  23. Dombrowski C, Levesque ML, Morel ML, Rouillard P, Morgan K, Rousseau F (2002) Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet 11(4):371–378PubMedGoogle Scholar
  24. Farzin F, Perry H, Hessl D, Loesch D, Cohen J, Bacalman S, Gane L, Tassone F, Hagerman P, Hagerman R (2006) Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr 27(2 Suppl):S137–S144PubMedGoogle Scholar
  25. Fernandez-Carvajal I, Walichiewicz P, Xiaosen X, Pan R, Hagerman PJ, Tassone F (2009) Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn 11(4):324–329PubMedGoogle Scholar
  26. Franke P, Leboyer M, Gansicke M, Weiffenbach O, Biancalana V, Cornillet-Lefebre P, Croquette MF, Froster U, Schwab SG, Poustka F, Hautzinger M, Maier W (1998) Genotype-phenotype relationship in female carriers of the premutation and full mutation of FMR-1. Psychiatry Res 80(2):113–127PubMedGoogle Scholar
  27. Garcia-Arocena D, Yang JE, Brouwer JR, Tassone F, Iwahashi C, Berry-Kravis EM, Goetz CG, Sumis AM, Zhou L, Nguyen DV, Campos L, Howell E, Ludwig A, Greco C, Willemsen R, Hagerman RJ, Hagerman PJ (2010) Fibroblast phenotype in male carriers of FMR1 premutation alleles. Hum Mol Genet 19(2):299–312PubMedGoogle Scholar
  28. Gokden M, Al-Hinti JT, Harik SI (2009) Peripheral nervous system pathology in fragile X tremor/ataxia syndrome (FXTAS). Neuropathology 29(3):280–284PubMedGoogle Scholar
  29. Greco CM, Hagerman RJ, Tassone F, Chudley A, Del Bigio MR, Jacquemont S, Leehey M, Hagerman PJ (2002) Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 125(8):1760–1771PubMedGoogle Scholar
  30. Greco CM, Berman RF, Martin RM, Tassone F, Schwartz PH, Chang A, Trapp BD, Iwahashi C, Brunberg J, Grigsby J, Hessl D, Becker EJ, Papazian J, Leehey MA, Hagerman RJ, Hagerman PJ (2006) Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 129(Pt 1):243–255PubMedGoogle Scholar
  31. Greco CM, Soontarapornchai K, Wirojanan J, Gould JE, Hagerman PJ, Hagerman RJ (2007) Testicular and pituitary inclusion formation in fragile X associated tremor/ataxia syndrome. J Urol 177(4):1434–1437PubMedGoogle Scholar
  32. Greco CM, Tassone F, Garcia-Arocena D, Tartaglia N, Coffey SM, Vartanian TK, Brunberg JA, Hagerman PJ, Hagerman RJ (2008) Clinical and neuropathologic findings in a woman with the FMR1 premutation and multiple sclerosis. Arch Neurol 65(8):1114–1116PubMedGoogle Scholar
  33. Greco CM, Navarro CS, Hunsaker MR, Maezawa I, Shuler JF, Tassone F, Delany M, Au JW, Berman RF, Jin LW, Schumann C, Hagerman PJ, Hagerman R (2011) Neuropathologic features in the hippocampus and cerebellum of three older men with fragile X syndrome. Mol Autism 2(1):2PubMedGoogle Scholar
  34. Grigsby J, Brega AG, Jacquemont S, Loesch DZ, Leehey MA, Goodrich GK, Hagerman RJ, Epstein J, Wilson R, Cogswell JB, Jardini T, Tassone F, Hagerman PJ (2006a) Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS). J Neurol Sci 248(1–2):227–233PubMedGoogle Scholar
  35. Grigsby J, Leehey MA, Jacquemont S, Brunberg JA, Hagerman RJ, Wilson R, Epstein JH, Greco CM, Tassone F, Hagerman PJ (2006b) Cognitive impairment in a 65-year-old male with the fragile X-associated tremor-ataxia syndrome (FXTAS). Cogn Behav Neurol 19(3):165–171PubMedGoogle Scholar
  36. Grigsby J, Brega AG, Engle K, Leehey MA, Hagerman RJ, Tassone F, Hessl D, Hagerman PJ, Cogswell JB, Bennett RE, Cook K, Hall DA, Bounds LS, Paulich MJ, Reynolds A (2008) Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. Neuropsychology 22(1):48–60PubMedGoogle Scholar
  37. Hagerman RJ, Hagerman PJ (2002) The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev 12:278–283PubMedGoogle Scholar
  38. Hagerman PJ, Hagerman RJ (2004) The fragile-X premutation: a maturing perspective. Am J Hum Genet 74(5):805–816PubMedGoogle Scholar
  39. Hagerman RJ, Staley LW, O’Connor R, Lugenbeel K, Nelson D, McLean SD, Taylor A (1996) Learning-disabled males with a fragile X CGG expansion in the upper premutation size range. Pediatrics 97(1):122–126PubMedGoogle Scholar
  40. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, Grigsby J, Gage B, Hagerman PJ (2001) Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 57:127–130PubMedGoogle Scholar
  41. Hagerman RJ, Leavitt BR, Farzin F, Jacquemont S, Greco CM, Brunberg JA, Tassone F, Hessl D, Harris SW, Zhang L, Jardini T, Gane LW, Ferranti J, Ruiz L, Leehey MA, Grigsby J, Hagerman PJ (2004) Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 74(5):1051–1056PubMedGoogle Scholar
  42. Hagerman RJ, Coffey SM, Maselli R, Soontarapornchai K, Brunberg JA, Leehey MA, Zhang L, Gane LW, Fenton-Farrell G, Tassone F, Hagerman PJ (2007) Neuropathy as a presenting feature in fragile X-associated tremor/ataxia syndrome. Am J Med Genet A 143(19):2256–2260Google Scholar
  43. Hagerman RJ, Hall DA, Coffey S, Leehey M, Bourgeois J, Gould J, Zhang L, Seritan A, Berry-Kravis E, Olichney J, Miller JW, Fong AL, Carpenter R, Bodine C, Gane LW, Rainin E, Hagerman H, Hagerman PJ (2008) Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging 3(2):251–262PubMedGoogle Scholar
  44. Hagerman R, Hoem G, Hagerman P (2010) Fragile X and autism: intertwined at the molecular level leading to targeted treatments. Mol Autism 1(1):12PubMedGoogle Scholar
  45. Hall DA, Berry-Kravis E, Jacquemont S, Rice CD, Cogswell J, Zhang L, Hagerman RJ, Hagerman PJ, Leehey MA (2005) Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS). Neurology 65(2):299–301PubMedGoogle Scholar
  46. Hall DA, Berry-Kravis E, Hagerman RJ, Hagerman PJ, Rice CD, Leehey MA (2006) Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome. Mov Disord 21(10):1741–1744PubMedGoogle Scholar
  47. Hall DA, Howard K, Hagerman R, Leehey MA (2009) Parkinsonism in FMR1 premutation carriers may be indistinguishable from Parkinson disease. Parkinsonism Relat Disord 15(2):156–159PubMedGoogle Scholar
  48. Hashem V, Galloway JN, Mori M, Willemsen R, Oostra BA, Paylor R, Nelson DL (2009) Ectopic expression of CGG containing mRNA is neurotoxic in mammals. Hum Mol Genet 18(13):2443–2451PubMedGoogle Scholar
  49. Hashimoto R, Javan A, Tassone F, Hagerman R, Rivera S (2011a) A Voxel-based morphometry study of grey matter loss in Fragile X-associated Tremor/Ataxia Syndrome. Brain 134(Pt3):863–878PubMedGoogle Scholar
  50. Hashimoto RI, Backer KC, Tassone F, Hagerman RJ, Rivera SM (2011b) An fMRI study of the prefrontal activity during the performance of a working memory task in premutation carriers of the fragile X mental retardation 1 gene with and without fragile X-associated tremor/ataxia syndrome (FXTAS). J Psychiatr Res 45(1):36–43PubMedGoogle Scholar
  51. Hessl D, Tassone F, Loesch DZ, Berry-Kravis E, Leehey MA, Gane LW, Barbato I, Rice C, Gould E, Hall DA, Grigsby J, Wegelin JA, Harris S, Lewin F, Weinberg D, Hagerman PJ, Hagerman RJ (2005) Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet B Neuropsychiatr Genet 139(1):115–121Google Scholar
  52. Hessl D, Rivera S, Koldewyn K, Cordeiro L, Adams J, Tassone F, Hagerman PJ, Hagerman RJ (2007) Amygdala dysfunction in men with the fragile X premutation. Brain 130(Pt 2):404–416PubMedGoogle Scholar
  53. Hunsaker MR, Greco CM, Spath M, Smits A, Navarro CS, Tassone F, Kros JM, Severijnen L, Berry-Kravis E, Berman RF, Hagerman PJ, Willemsen R, Hagerman RJ, Hukema RK In Press. Parallel non-CNS Organ Pathology in Fragile X PM Carriers with FXTAS and CGG Knock-In Mice. Acta NeuropatholGoogle Scholar
  54. Hunsaker MR, Goodrich-Hunsaker NJ, Willemsen R, Berman RF (2010) Temporal ordering deficits in female CGG KI mice heterozygous for the fragile X premutation. Behav Brain Res 213(2):263–268PubMedGoogle Scholar
  55. Hunsaker MR, Greco CM, Tassone F, Berman RF, Willemsen R, Hagerman RJ, Hagerman PJ. (2011) Rare intranuclear inclusions in the brains of 3 older adult males with fragile x syndrome: implications for the spectrum of fragile x-associated disorders. J Neuropathol Exp Neurol 70(6):462–9.PubMedGoogle Scholar
  56. Iwahashi CK, Yasui DH, An HJ, Greco CM, Tassone F, Nannen K, Babineau B, Lebrilla CB, Hagerman RJ, Hagerman PJ (2006) Protein composition of the intranuclear inclusions of FXTAS. Brain 129(Pt 1):256–271PubMedGoogle Scholar
  57. Jacobs BL, Praag H, Gage FH (2000) Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 5(3):262–269PubMedGoogle Scholar
  58. Jacquemont S (2005) Screening for FXTAS. Eur J Hum Genet 13(1):2–3PubMedGoogle Scholar
  59. Jacquemont S, Hagerman RJ, Leehey M, Grigsby J, Zhang L, Brunberg JA, Greco C, Des Portes V, Jardini T, Levine R, Berry-Kravis E, Brown WT, Schaeffer S, Kissel J, Tassone F, Hagerman PJ (2003) Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 72(4):869–878PubMedGoogle Scholar
  60. Jacquemont S, Farzin F, Hall D, Leehey M, Tassone F, Gane L, Zhang L, Grigsby J, Jardini T, Lewin F, Berry-Kravis E, Hagerman PJ, Hagerman RJ (2004) Aging in individuals with the FMR1 mutation. Am J Ment Retard 109(2):154–164PubMedGoogle Scholar
  61. Jin P, Zarnescu DC, Zhang F, Pearson CE, Lucchesi JC, Moses K, Warren ST (2003) RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in drosophila. Neuron 39:739–747PubMedGoogle Scholar
  62. Kamm C, Healy DG, Quinn NP, Wullner U, Moller JC, Schols L, Geser F, Burk K, Borglum AD, Pellecchia MT, Tolosa E, del Sorbo F, Nilsson C, Bandmann O, Sharma M, Mayer P, Gasteiger M, Haworth A, Ozawa T, Lees AJ, Short J, Giunti P, Holinski-Feder E, Illig T, Wichmann HE, Wenning GK, Wood NW, Gasser T (2005) The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain 128(Pt 8):1855–1860PubMedGoogle Scholar
  63. Kenneson A, Zhang F, Hagedorn CH, Warren ST (2001) Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet 10(14):1449–1454PubMedGoogle Scholar
  64. Khalil AM, Faghihi MA, Modarresi F, Brothers SP, Wahlestedt C (2008) A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. PLoS One 3(1):e1486PubMedGoogle Scholar
  65. Koldewyn K, Hessl D, Adams J, Tassone F, Hagerman RJ, Hagerman PJ, Rivera SM (2008) Reduced hippocampal activation during recall is associated with elevated FMR1 mRNA and psychiatric symptoms in men with the fragile X premutation. Brain Imaging Behav 2(2):105–116PubMedGoogle Scholar
  66. Ladd PD, Smith LE, Rabaia NA, Moore JM, Georges SA, Hansen RS, Hagerman RJ, Tassone F, Tapscott SJ, Filippova GN (2007) An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet 16(24):3174–3187PubMedGoogle Scholar
  67. Leehey M, Legg W, Tassone F, Hagerman R. (In Press) Fibromyalgia in fragile X mental retardation 1 gene premutation carriers. RheumatologyGoogle Scholar
  68. Leehey MA, Munhoz RP, Lang AE, Brunberg JA, Grisby J, Greco C, Jacquemont S, Tassone F, Lozano AM, Hagerman PJ, Hagerman RJ (2003) The fragile X premutation presenting as essential tremor. Arch Neurol 60:117–121PubMedGoogle Scholar
  69. Leehey MA, Berry-Kravis E, Min SJ, Hall DA, Rice CD, Zhang L, Grigsby J, Greco CM, Reynolds A, Lara R, Cogswell J, Jacquemont S, Hessl DR, Tassone F, Hagerman R, Hagerman PJ (2007) Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord 22(2):203–206PubMedGoogle Scholar
  70. Leehey MA, Berry-Kravis E, Goetz CG, Zhang L, Hall DA, Li L, Rice CD, Lara R, Cogswell J, Reynolds A, Gane L, Jacquemont S, Tassone F, Grigsby J, Hagerman RJ, Hagerman PJ (2008) FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology 70(16 Pt 2):1397–1402PubMedGoogle Scholar
  71. Loesch DZ, Churchyard A, Brotchie P, Marot M, Tassone F (2005) Evidence for, and a spectrum of, neurological involvement in carriers of the fragile X pre-mutation: FXTAS and beyond. Clin Genet 67(5):412–417PubMedGoogle Scholar
  72. Loesch D, Sherwell S, Kinsella G, Tassone F, Taylor A, Amor D, Sung S, Evans A. (2011) Fragile X-associated tremor/ataxia phenotype in a male carrier of unmethylated full mutation in the FMR1 gene. Clin GenetGoogle Scholar
  73. Louis E, Moskowitz C, Friez M, Amaya M, Vonsattel JP (2006) Parkinsonism, dysautonomia, and intranuclear inclusions in a fragile X carrier: a clinical-pathological study. Mov Disord 21(3):420–425PubMedGoogle Scholar
  74. McConkie-Rosell A, Abrams L, Finucane B, Cronister A, Gane LW, Coffey SM, Sherman S, Nelson LM, Berry-Kravis E, Hessl D, Chiu S, Street N, Vatave A, Hagerman RJ (2007) Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders. J Genet Couns 16(5):593–606PubMedGoogle Scholar
  75. Mothersead PK, Conrad K, Hagerman RJ, Greco CM, Hessl D, Tassone F (2005) GRAND ROUNDS: an atypical progressive dementia in a male carrier of the fragile X premutation: an example of fragile X-associated tremor/ataxia syndrome. Appl Neuropsychol 12(3):169–178PubMedGoogle Scholar
  76. Ngai S, Tang YM, Du L, Stuckey S (2006) Hyperintensity of the middle cerebellar peduncles on fluid-attenuated inversion recovery imaging: variation with age and implications for the diagnosis of multiple system atrophy. AJNR Am J Neuroradiol 27(10):2146–2148PubMedGoogle Scholar
  77. Nolin SL, Brown WT, Glicksman A, Houck GE Jr, Gargano AD, Sullivan A, Biancalana V, Brondum-Nielsen K, Hjalgrim H, Holinski-Feder E, Kooy F, Longshore J, Macpherson J, Mandel JL, Matthijs G, Rousseau F, Steinbach P, Vaisanen ML, von Koskull H, Sherman SL (2003) Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet 72(2):454–464PubMedGoogle Scholar
  78. O’Dwyer JP, Clabby C, Crown J, Barton DE, Hutchinson M (2005) Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy. Neurology 65(2):331–332PubMedGoogle Scholar
  79. Ortigas MC, Bourgeois JA, Schneider A, Olichney J, Nguyen DV, Cogswell JB, Hall DA, Hagerman RJ (2010) Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine. J Clin Psychopharmacol 30(5):642–644PubMedGoogle Scholar
  80. Paul R, Pessah IN, Gane L, Ono M, Hagerman PJ, Brunberg JA, Tassone F, Bourgeois JA, Adams PE, Nguyen DV, Hagerman R (2010) Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxins. Neurotoxicology 31(4):399–402PubMedGoogle Scholar
  81. Peprah E, He W, Allen E, Oliver T, Boyne A, Sherman SL (2010) Examination of FMR1 transcript and protein levels among 74 premutation carriers. J Hum Genet 55(1):66–68PubMedGoogle Scholar
  82. Peters N, Kamm C, Asmus F, Holinski-Feder E, Kraft E, Dichgans M, Bruning R, Gasser T, Botzel K (2006) Intrafamilial variability in fragile X-associated tremor/ataxia syndrome. Mov Disord 21:98–102PubMedGoogle Scholar
  83. Primerano B, Tassone F, Hagerman RJ, Hagerman PJ, Amaldi F, Bagni C (2002) Reduced FMR1 mRNA translation efficiency in Fragile X patients with premutations. RNA 8(12):1482–1488PubMedGoogle Scholar
  84. Riddle JE, Cheema A, Sobesky WE, Gardner SC, Taylor AK, Pennington BF, Hagerman RJ (1998) Phenotypic involvement in females with the FMR1 gene mutation. Am J Ment Retard 102(6):590–601PubMedGoogle Scholar
  85. Ristori G, Romano S, Visconti A, Cannoni S, Spadaro M, Frontali M, Pontieri FE, Vanacore N, Salvetti M (2010) Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 74(10):839–845PubMedGoogle Scholar
  86. Roberts JE, Chapman RS, Warren SF (2008) Speech and language development and intervention in down syndrome and fragile X syndrome. Paul H. Brookes, Baltimore, MDGoogle Scholar
  87. Rodriguez-Revenga L, Madrigal I, Alegret M, Santos M, Mila M (2008) Evidence of depressive symptoms in fragile-X syndrome premutated females. Psychiatr Genet 18(4):153–155PubMedGoogle Scholar
  88. Rodriguez-Revenga L, Madrigal I, Pagonabarraga J, Xuncla M, Badenas C, Kulisevsky J, Gomez B, Mila M (2009) Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet 17(10):1359–1362PubMedGoogle Scholar
  89. Ross-Inta C, Omanska-Klusek A, Wong S, Barrow C, Garcia-Arocena D, Iwahashi C, Berry-Kravis E, Hagerman RJ, Hagerman PJ, Giulivi C (2010) Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome. Biochem J 429(3):545–552PubMedGoogle Scholar
  90. Rousseau F, Rouillard P, Morel ML, Khandjian EW, Morgan K (1995) Prevalence of carriers of premutation-size alleles of the FMRI gene- and implications for the population genetics of the fragile X syndrome. Am J Hum Genet 57(5):1006–1018PubMedGoogle Scholar
  91. Sellier C, Rau F, Liu Y, Tassone F, Hukema RK, Gattoni R, Schneider A, Richard S, Willemsen R, Elliott DJ, Adams JS (2010) Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J 29(7):1248–1261PubMedGoogle Scholar
  92. Seritan AL, Nguyen DV, Farias ST, Hinton L, Grigsby J, Bourgeois JA, Hagerman RJ (2008) Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 147B(7):1138–1144PubMedGoogle Scholar
  93. Sevin M, Kutalik Z, Bergman S, Vercelletto M, Renou P, Lamy E, Vingerhoets FJ, Di Virgilio G, Boisseau P, Bezieau S, Pasquier L, Rival JM, Beckmann JS, Damier P, Jacquemont S (2009) Penetrance of marked cognitive impairment in older male carriers of the FMR1 gene premutation. J Med Genet 46(12):818–824PubMedGoogle Scholar
  94. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H (2010) Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One 5(9):e12244PubMedGoogle Scholar
  95. Sobesky WE, Taylor AK, Pennington BF, Bennetto L, Porter D, Riddle J, Hagerman RJ (1996) Molecular-clinical correlations in females with fragile X. Am J Med Genet 64(2):340–345PubMedGoogle Scholar
  96. Soontarapornchai K, Maselli R, Fenton-Farrell G, Tassone F, Hagerman PJ, Hessl D, Hagerman RJ (2008) Abnormal nerve conduction features in fragile X premutation carriers. Arch Neurol 65(4):495–498PubMedGoogle Scholar
  97. Storey E, Billimoria P (2005) Increased T2 signal in the middle cerebellar peduncles on MRI is not specific for fragile X premutation syndrome. J Clin Neurosci 12:42–43PubMedGoogle Scholar
  98. Tassone FB-K, Elizabeth M (2010) The fragile X-associated tremor ataxia syndrome (FXTAS). Springer, New york, p 188Google Scholar
  99. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ (2000) Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 66(1):6–15PubMedGoogle Scholar
  100. Tassone F, Hagerman RJ, Garcia-Arocena D, Khandjian EW, Greco CM, Hagerman PJ (2004) Intranuclear inclusions in neural cells with premutation alleles in fragile X associated tremor/ataxia syndrome. J Med Genet 41(4):e43PubMedGoogle Scholar
  101. Tassone F, Adams J, Berry-Kravis EM, Cohen SS, Brusco A, Leehey MA, Li L, Hagerman RJ, Hagerman PJ (2007) CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet B Neuropsychiatr Genet 144B(4):566–569PubMedGoogle Scholar
  102. Toledano-Alhadef H, Basel-Vanagaite L, Magal N, Davidov B, Ehrlich S, Drasinover V, Taub E, Halpern GJ, Ginott N, Shohat M (2001) Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet 69:351–360PubMedGoogle Scholar
  103. Van Dam D, Errijgers V, Kooy RF, Willemsen R, Mientjes E, Oostra BA, De Deyn PP (2005) Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS). Behav Brain Res 162(2):233–239PubMedGoogle Scholar
  104. Wegiel J, Kuchna I, Nowicki K, Imaki H, Marchi E, Ma SY, Chauhan A, Chauhan V, Bobrowicz TW, de Leon M, Louis LA, Cohen IL, London E, Brown WT, Wisniewski T (2010) The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropathol 119(6):755–770PubMedGoogle Scholar
  105. Wenzel HJ, Hunsaker MR, Greco CM, Willemsen R, Berman RF (2010) Ubiquitin-positive intranuclear inclusions in neuronal and glial cells in a mouse model of the fragile X premutation. Brain Res 1318:155–166PubMedGoogle Scholar
  106. Willemsen R, Hoogeveen-Westerveld M, Reis S, Holstege J, Severijnen LA, Nieuwenhuizen IM, Schrier M, Van Unen L, Tassone F, Hoogeveen AT, Hagerman PJ, Mientjes EJ, Oostra BA (2003) The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum Mol Genet 12(9):949–959PubMedGoogle Scholar
  107. Zesiewicz TA, Sullivan KL, Gooch CL, Lynch DR (2009) Subjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix). J Clin Neuromuscul Dis 10(4):191–193PubMedGoogle Scholar
  108. Zhang L, Coffey S, Lua LL, Greco CM, Schafer JA, Brunberg J, Borodyanskaya M, Agius MA, Apperson M, Leehey M, Tartaglia N, Tassone F, Hagerman PJ, Hagerman RJ (2009) FMR1 premutation in females diagnosed with multiple sclerosis. J Neurol Neurosurg Psychiatry 80(7):812–814PubMedGoogle Scholar
  109. Zuhlke C, Budnik A, Gehlken U, Dalski A, Purmann S, Naumann M, Schmidt M, Burk K, Schwinger E (2004) FMR1 premutation as a rare cause of late onset ataxia – evidence for FXTAS in female carriers. J Neurol 251(11):1418–1419PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.M.I.N.D.-InstituteUniversity of California-Davis Medical CenterSacramentoUSA
  2. 2.Department of Biochemistry and Molecular MedicineUniversity of California, School of MedicineDavisUSA
  3. 3.Department of PediatricsUniversity of California-Davis Medical CenterSacramentoUSA

Personalised recommendations